Acuvax cashes in RESprotect
Wednesday, 15 April, 2009
Vaccine developer Acuvax, formerly known as Avantogen, has sold its 10 per cent stake in a German company to raise cash.
The German company, RESprotect, is the original inventor and developer of pancreatic cancer drug RP101, the North American rights to which Acuvax owns 43 per cent.
The drug is being developed in North America by Acuvax’s partner SciClone Pharmaceuticals, which owns the majority rights. RESprotect retains the rights in the rest of the world.
The Brisbane company, which is also affiliated with dengue fever developer Hawaii Biotech, said the sale was worth $750,000 and would bring in $410,000 in cash.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
